| Trial ID: | L0774 |
| Source ID: | IRCT20150124020765N2
|
| Associated Drug: |
Cranberry
|
| Title: |
Effect of combined dietary weight loss and cranberry supplementation on hepatic enzymes, steatosis and inflammatory, antioxidant and apoptosis biomarkers in patients with Non-alcoholic fatty liver disease
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic fatty liver disease. <br>Fatty (change of) liver, not elsewhere classified
|
| Interventions: |
Intervention 1: Intervention group: dietary weight loss and 2 capsules containing 288 mg Cranberry extract for 12 weeks. Intervention 2: Control group: dietary weight loss and 2 placebo capsules for 12 weeks.
|
| Outcome Measures: |
Fatty liver grade (Steatosis). Timepoint: At baseline and after 12 weeks. Method of measurement: ultrasonography.;Alanine transaminase. Timepoint: At baseline and after 12 weeks. Method of measurement: enzymatic colorimetric assay.;Aspartate aminotransferase. Timepoint: At baseline and after 12 weeks. Method of measurement: Enzymatic colorimetric assay.;Alkaline phosphatase. Timepoint: At baseline and after 12 weeks. Method of measurement: Enzymatic colorimetric assay.;Monocyte chemoattractant protein 1 (Mcp-1)) ?? CCL2. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Ytokeratin-18. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Total antioxidant body. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Malondialdehyde. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Tumor necrosis factor alpha. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Lipid profile. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Insulin. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa.;Fasting blood sugar. Timepoint: At baseline and after 12 weeks. Method of measurement: Enzymatic colorimetric assay.nan
|
| Sponsor/Collaborators: |
Ahvaz University of Medical Sciences
|
| Gender: |
All
|
| Age: |
18 yearsno limit
|
| Phases: |
Phase 3
|
| Enrollment: |
50
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this study; we assume equal allocation of subjects to each group With blocked randomization. With a randomized bl
|
| Start Date: |
06/01/2019
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
29 January 2019
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/36005
|
